Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 325 of 372 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/08/20
End: 08/01/26
Due: 08/01/27
Phase: N/A
Priority: Normal
Start: 10/04/19
End: 08/01/26
Due: 08/01/27
Phase: N/A
Priority: Normal
Start: 03/28/24
End: 12/01/27
Due: 12/01/28
Phase: N/A
Priority: Normal
Start: 09/14/23
End: 10/01/26
Due: 10/01/27
Phase: N/A
Priority: Normal
Start: 05/31/09
End: -
Due: -
Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase: N/A
Priority: Normal
Start: 07/31/05
End: -
Due: -
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/06/23
End: 09/30/28
Due: 09/30/29
Phase: N/A
Priority: Normal
Start: 11/30/07
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/04
End: 07/31/06
Due: 07/31/07
Phase: N/A
Priority: Normal
Start: 06/14/18
End: 06/14/22
Due: 06/14/23
Phase: N/A
Priority: Normal
Start: 06/08/16
End: 12/12/18
Due: 12/12/19
Phase: N/A
Priority: Normal
Start: 08/25/15
End: 08/25/26
Due: 08/25/27
Phase: N/A
Priority: Normal
Start: 01/13/22
End: 01/07/27
Due: 01/07/28
Phase: N/A
Priority: Normal
Start: 11/08/23
End: 11/30/27
Due: 11/30/28
Phase: N/A
Priority: Normal
Start: 08/31/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/29/21
End: 11/01/26
Due: 11/01/27
Phase: N/A
Priority: Normal
Start: 01/14/20
End: 05/23/23
Due: 05/23/24
Phase: N/A
Priority: Normal
Start: 03/31/08
End: 07/31/26
Due: 07/31/27
Phase: N/A
Priority: Normal
Start: 07/10/19
End: 05/17/23
Due: 05/17/24
Phase: N/A
Priority: Normal
Start: 08/06/24
End: 12/01/30
Due: 12/01/31
Phase: N/A
Priority: Normal
Start: 05/31/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/98
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/31/04
End: 09/30/10
Due: 09/30/11
Phase: N/A
Priority: Normal
Start: 03/17/21
End: 01/01/27
Due: 01/01/28